Staurosporine

Catalog No.S1421 Synonyms: CGP 41251

Staurosporine Chemical Structure

Molecular Weight(MW): 466.53

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.

Size Price Stock Quantity  
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Caspase-8, 9, 3, 6, PARP, and cleaved PARP were detected in POTEG overexpressed cells and control cells with or without STS treatment.

    Mol Carcinog, 2018, 57(7):886-895. Staurosporine purchased from Selleck.

    Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
Targets
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
In vitro

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells MkjQR5l1d3SxeHnjxsBie3OjeR?= M{HjblQ5KGh? MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NHWtNFYh|ryPLh?= NFi4RW0zOTN6OEG5NS=>
human colon cancer cell line (LoVo cells) MYrQdo9tcW[ncnH0bY9vKGG|c3H5 MlrORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiClb3zvckBk[W6lZYKgZ4VtdCCuaX7lJEhNd1[xIHPlcIx{MSC3c3nu[{BOXFRiYYPzZZktKEmFNUC9NE4xODFizszNMi=> MkKxNVE2QTF3MEW=
human LoVo cells M1H6fnBzd2yrZnXyZZRqd25iYYPzZZk> MVG0PEB1dyB5MjDo MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyxVn:gZ4VtdHNiYX\0[ZIhPDhidH:gO|IhcHK|IHL5JG1VXCCjc4PhfS=> Mo\2NlIyQDJ7Mkm=
P19 cells MoL3SpVv[3Srb36gZZN{[Xl? MX7Jcohq[mm2aX;uJI9nKFCuYYTlcIV1NWSncnn2[YQh\3Kxd4ToJIZi[3SxcjDy[YNmeHSxcjDpckBROTliY3XscJMtKEmFNUC9NE4xODJizszNMi=> NUixOGU{OTV5N{G0NVk>
human BJ cells NUS5e25qS3m2b4TvfIlkyqCjc4PhfS=> M4TqflczKGh? MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCTkBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3HsZ4VqdiCDTTDhd5NigSxiSVO1NF0xNjByMjFOwG0v M{\5cFIzQTJzMEix
human HT-29 cells MX7GeY5kfGmxbjDhd5NigQ>? NIWxVZQzKGh? NELyd2RG\m[nY4Sgc44hdWm2b3Poc45lemmjbDDt[Y1jemGwZTDwc5RmdnSrYXygbY4hcHWvYX6gTHQuOjliY3XscJMh[W[2ZYKgNkBpenNidYPpcochUkNvMTDzeIFqdmmwZzDifUBndHWxcnXzZ4Vv[2ViYYPzZZk> M1XKTVIyPDJ6M{e1
human A549 cells NVX3d|Q{S3m2b4TvfIlkyqCjc4PhfS=> M4e4OlczKGh? NYn6e|VsS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBu\XSqb3S= Mn3CNVg1QDR5N{W=
human HT-29 cells NWXqWo9QTnWwY4Tpc44h[XO|YYm= M1O2eWlvcGmkaYTpc44hd2ZibXn0c4Npd26mcnnhcEBu\W2kcnHu[UBxd3SnboTpZYwhcW5iaIXtZY4hUFRvMkmgZ4VtdHNidYPpcochUkNzIHT5[UB{fGGrbnnu[{BjgSCobIXvdoV{[2WwY3WgdIxifGVicnXh[IVzKGG|c3H5MEBKSzVyPUKuOUBvVQ>? NHPpNW0zOTVzM{K5Ny=>
human HT-29 cells MmnZSpVv[3Srb36gZZN{[Xl? NInXOFIzKGh? NVLHU29lUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBz\WS3Y4Tpc44hd2ZibXn0c4Npd26mcnnhcEBu\W2kcnHu[UBxd3SnboTpZYwh[W[2ZYKgNkBpenNiYomgeZNqdmdiSlOxJJN1[WmwaX7nJIJ6KG[udX;y[ZNk\W6lZTDj[YxtNWKjc3XkJIF{e2G7LDDFR|UxRTJwNjDuUU4> MX2yNVk4OzFyMR?=
Sf9 cells NHvKdlVHfW6ldHnvckBie3OjeR?= NH[0fXNKdmirYnn0bY9vKG:oIHj1cYFvKFO7azDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{NCCLQ{WwQVMhdk1w M1PyT|E5QDJ|N{i0
human HUVEC MVfQdo9tcW[ncnH0bY9vKGG|c3H5 NYDqSnBtPDhidH:gO|IhcA>? NXPvVXJFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWXZGSyCjZoTldkA1QCC2bzC3NkBpenNiYomgUXRVKGG|c3H5 NUT4XGNyOjJzOEK5Nlk>
P19 cells NFPDZVZHfW6ldHnvckBie3OjeR?= M{S2NmlvcGmkaYTpc44hd2ZiUILveIVqdiCNaX7hd4UhSSCrbjDQNVkh[2WubIOsJGlEPTB;NDDuUU4> MnPDNVU4PzF2MUm=
Sf9 cells MlHoSpVv[3Srb36gZZN{[Xl? NXfRco9uUW6qaXLpeIlwdiCxZjDoeY1idiCIeX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCjZoTldkAyKG2rbjDifUBGVEmVQTDpckBxemW|ZX7j[UBw\iBzIIXtc4wwVCCDVGC= NFHZ[2cyPzNzNUi1Ny=>
Sf21 cells NXPncGx6TnWwY4Tpc44h[XO|YYm= M2C0WmlvcGmkaYTpc44hd2ZiSlHLN{BmgHC{ZYPz[YQhcW5iU3[yNUBk\WyuczygTWM2OD14IH7NMi=> NVvqO3lFOTdyOEiwOVk>
human colon carcinoma cell line HCT116 NV;uZ4I1TnWwY4Tpc44h[XO|YYm= NEHUTmVEd26lZX70doF1cW:wIILldZVqemWmIH\vdkBoem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBkd2yxbjDjZZJkcW6xbXGgZ4VtdCCuaX7lJGhEXDFzNjygTWM2OD14IH7NMi=> NEHOb4gyPTV|N{O0OS=>
human ST486 cells M1zyZnBzd2yrZnXyZZRqd25iYYPzZZk> MlHEOFghfG9iN{KgbC=> MljIRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVVES4OkBk\WyuczDh[pRmeiB2ODD0c{A4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVchdk1w MlLMNlIyQDJ7Mkm=
human MDA-MB-231 cells NIHVbYFEgXSxdH;4bYPDqGG|c3H5 MUK3NkBp MnSxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB5MjDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCvZYToc4QtKEeLNUC9O{4yKG6PLh?= MUGxPFQ5PDd5NR?=
P19 cells MYPGeY5kfGmxbjDhd5NigQ>? NF\CS4FKdmirYnn0bY9vKG:oIFP5Z4xqdi2mZYDlcoRmdnRia3nuZZNmKDFiaX6gVFE6KGOnbHzzMEBKSzVyPUigcm0v MUmxOVc4OTRzOR?=
human DLD1 cells MYDQdo9tcW[ncnH0bY9vKGG|c3H5 NXu1T2h6PDhvN{KgbC=> NXTHUllXSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDEUGQyKGOnbHzzJIFnfGW{IES4JJRwKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:QSCwTT6= NGLWfFczOjF6MkmyPS=>
insect cells M{j0TWZ2dmO2aX;uJIF{e2G7 MlrkTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSaX2xJIV5eHKnc4Pl[EBqdiCrboPlZ5Qh[2WubIOgZpkhUFSURjygTWM2OD1zMDDuUU4> NVq3OWNuOTlzN{mwO|Y>
V79 MZ cells NGWzbW9HfW6ldHnvckBie3OjeR?= MmTZTY5pcWKrdHnvckBw\iCqdX3hckBidGSxc4Tldo9v\SC|eX70bIF{\SCneIDy[ZN{\WRiaX6gWlc6KE2cIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[Wymb4P0[ZJwdmVic4nueIhme2m|LDDJR|UxRTFzIH7NMi=> MX6yOFQzOjVzOR?=
P19 cells NX3mR2RVTnWwY4Tpc44h[XO|YYm= M4jhXGlvcGmkaYTpc44hd2ZiVnHzZ5Vt[XJiZX7kc5Rp\WyrYXyg[5Jwf3SqIH\hZ5RweiC{ZXPldJRweiCrbjDQNVkh[2WubIOsJGlEPTB;MUSgcm0v MoXJNVU4PzF2MUm=
Sf9 cells Mm\OSpVv[3Srb36gZZN{[Xl? NHzINmczOCCvaX7z NETm[2dKdmirYnn0bY9vKG:oIHj1cYFvKE[7bjDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KGGodHXyJFIxKG2rboOgZpkhTUyLU1GgbY4heHKnc3XuZ4Uhd2ZiMTD1cY9tN0xiQWTQMEBKSzVyPUG1JI5ONg>? MkHWNVc{OTV6NUO=
human PBMC M3TWT2Z2dmO2aX;uJIF{e2G7 NV3aVoh{OjRiaB?= NGDjVGJUfXCycnXzd4lwdiCxZjDJUFIheHKxZIXjeIlwdiCrbjDoeY1idiCSQl3DJIFnfGW{IEK0JIhzeyCkeTDFUGlUSSxiSVO1NF0yPiCwTT6= MkT2NVg2QDVyNE[=
human A549 cells MV;DfZRwfG:6aXRCpIF{e2G7 MnLDOFghcA>? NYHTXHpwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6KCxiSVO1NF0zOCCwTT6= MVmyOVgzPTl|NB?=
human CEM cells NGjUcGpEgXSxdH;4bYPDqGG|c3H5 NXGwRZp5PzJiaB?= MoPOR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2VOKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDZYxk\WmwIFHNJIF{e2G7LDDJR|UxRTJ|IH7NMi=> NIHZUFUzOjl{MUC4NS=>
human HeLa cells NFjDUIhEgXSxdH;4bYPDqGG|c3H5 MVW0PEBp MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MkWgcm0v NYnwdY9TOjV6MkW5N|Q>
human PC3 cells NXHzfop1S3m2b4TvfIlkyqCjc4PhfS=> Mn:xOFghcA>? NX\jW4E2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZkhNCCLQ{WwQVMyKG6PLh?= NXHrSYh6OjV6MkW5N|Q>
human SF268 cells Ml7MR5l1d3SxeHnjxsBie3OjeR?= MYS0PEBp MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTSlI3QCClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUS0JI5ONg>? M3W2cVIyPTF|Mkm0
human MCF7 cells MWrDfZRwfG:6aXRCpIF{e2G7 MmPuOFghcA>? NVjCcI05S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVUxKG6PLh?= NVvRXGI{OjF|OEixPVE>
HEK293 cells M2qySGN6fG:2b4jpZ:Kh[XO|YYm= NIP3PG04OiCq NXT3Wms6S3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYLHcI8h[XO|YYmsJGlEPTB;NU[gcm0v NYPoUJE{OjR5NkOyOlI>
HUE cells MWjGeY5kfGmxbjDhd5NigQ>? NWLxXVJSQTBibXnudy=> NVyy[2ZVUW6qaXLpeIlwdiCxZjDWSWdHWjJiaX6gTHVGKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gWmVITi2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25idILlZZRm\CCob4KgPVAhdWmwczDi[YZwemViVlXHSkBkcGGubHXu[4Uh[nliRVzJV2EtKEmFNUC9O|Ahdk1w NXKyT3pmOjBzN{CxOlM>
human A431 cells NHWwbJVEgXSxdH;4bYPDqGG|c3H5 M3K4c|I1KCCq NVfvUG5IS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR|MTDj[YxteyCjZoTldkAzPCCqcoOgeZNqdmdiQX7u[ZhqdiCYZV\JWGMweHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{BjgSCPVGSgZZN{[XluIFnDOVA:PzBibl2u MXyyNlU1OTB3MR?=
human Jurkat cells NEHHTpFRem:uaX\ldoF1cW:wIHHzd4F6 NUiyZ3pJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBLSUt|IHX4dJJme3OrbnegTWwzNXO2aX31cIF1\WRiaIXtZY4hUnW{a3H0JINmdGy|LDDJR|UxRTdzIH7NMi=> NHLsSnIyQTR{N{KwNy=>
HEK293 cells MmXaSpVv[3Srb36gZZN{[Xl? NIjRfG1KdmirYnn0bY9vKG:oIFnMMVghemWuZXHz[UBjgSCKRVuyPVMh[2WubIOg[ZhxemW|c3nu[{BRU0NvYnX0ZVItKEmFNUC9O|chdk1w MkLvNVU4PzF2MUm=
human KE-97 cells NH;rOFJEgXSxdH;4bYPDqGG|c3H5 MkezO|IhcA>? MoruR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2UuQTdiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTy[U1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOyEQvF2u NX[0WVJMOjR|MkiyPFM>
human CHOK1 cells MU\DfZRwfG:6aXRCpIF{e2G7 MUW0PEBp Mn;XR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2hQUzFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4Phfg+9lCCLQ{WwQVAvOTNizszNMi=> M1PuUlIyPTF|Mkm0
mouse NIH/3T3 cells MmPqR5l1d3SxeHnjxsBie3OjeR?= NITiTI46PiCq NYTjVmFGS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhVkmKL{PUN{Bk\WyuczDh[pRmeiB7NjDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTBwMjFOwG0v NUnPbnAzOjR|NkG1NlE>
human A2780 cells MkXPR5l1d3SxeHnjxsBie3OjeR?= NH\zXlg6PiCq M2r5SWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4zKM7:TT6= MVKyOFM3OTV{MR?=
human 8505C cells MXrDfZRwfG:6aXRCpIF{e2G7 NIDYT3I6PiCq NXXEUFBSS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hQDVyNVOgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjJizszNMi=> M4XHT|I1OzZzNUKx
human 518A2 cells NYH1RnNLS3m2b4TvfIlkyqCjc4PhfS=> NIO1W3Y6PiCq MkT5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gOVE5STJiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4Phfg+9lCCLQ{WwQVAvOiEQvF2u MXWyOFM3OTV{MR?=
human HuH7 cells MkTXR5l1d3SxeHnjxsBie3OjeR?= NFfSW284OiCq MlPwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTJVJPyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdILlMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{KM7:TT6= Ml[0NlQ{Ojh{OEO=
FL5.12-Akt1 cells MlfJVJJwdGmoZYLheIlwdiCjc4PhfS=> NYG0V3A2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBHVDVwMUKtRYt1OSClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5{OTFOwG0v MUWxOlQxOzZ{Nh?=
human MiaPaCa-2 cells M4jVRXBzd2yrZnXyZZRqd25iYYPzZZk> MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2rYWDhR4EuOiClZXzsd{whUUN3ME2wMlM4KM7:TT6= MWCxOlQyOzd6MB?=
human BGC823 cells M{HGc2N6fG:2b4jpZ:Kh[XO|YYm= NWnzTHdYPzJiaB?= MlzYR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmdEQDJ|IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0doUuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzhizszNMi=> NXfJeW9lOjR|MkiyPFM>
human MCF7 cells NVfaNFU1S3m2b4TvfIlkyqCjc4PhfS=> MmXrPVYhcA>? MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD60JO69VS5? MUeyOFM3OTV{MR?=
human A549 cells NGXt[HFEgXSxdH;4bYPDqGG|c3H5 NH\UZ5k6PiCq MnHRR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuOkDPxE1w NFPT[WEzPDN4MUWyNS=>
HEK293 cells M3fxOGN6fG:2b4jpZ:Kh[XO|YYm= MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNuIFXDOVA:OiEQvF2u M{K1bFI2OzF4M{G3
human Raji cells  NED1OlZEgXSxdH;4bYPDqGG|c3H5 NXfTXZg4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWmGsaTDj[YxteyxiRVO1NF0zKM7:TT6= MmLVNlU{OTZ|MUe=
human HepG2 cells MX\DfZRwfG:6aXRCpIF{e2G7 NVrFb2U1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNuIFXDOVA:OiEQvF2u NVjBTolZOjV|MU[zNVc>
human BJ cells NXvOS4hES3m2b4TvfIlkyqCjc4PhfS=> MmDsR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmoh[2WubIOsJGVEPTB;MjFOwG0v M1TsZlI2OzF4M{G3
human U937 cells MkfRR5l1d3SxeHnjxsBie3OjeR?= M{nuUWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU6OzdiY3XscJMtKEmFNUC9NkDPxE1w MVexO|A5QDB4Nx?=

... Click to View More Cell Line Experimental Data

In vivo In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
Cell Research:

[3]

+ Expand
  • Cell lines: PC12
  • Concentrations: Dissolved in DMSO, final concentration 1 μM
  • Incubation Time: ~32 hours
  • Method:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (Only for Reference)
Animal Research:

[8]

+ Expand
  • Animal Models: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~10 ng
  • Administration: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 466.53
Formula

C28H26N4O3

CAS No. 62996-74-1
Storage powder
in solvent
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00082017 Terminated Lymphoma Large-Cell Ki-1|Lymphoma T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5 2004 Phase 2
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00072267 Completed Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer University Health Network Toronto|National Cancer Institute (NCI) January 2004 Phase 2
NCT00072189 Terminated Recurrent Melanoma|Stage IV Melanoma National Cancer Institute (NCI) November 2003 Phase 2
NCT00030888 Unknown status Kidney Cancer University of California San Francisco|National Cancer Institute (NCI) December 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products0

Tags: buy Staurosporine | Staurosporine supplier | purchase Staurosporine | Staurosporine cost | Staurosporine manufacturer | order Staurosporine | Staurosporine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID